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Abstract
Objective: This study investigated the effects of low-dose tranexamic acid on post-coronary artery bypass surgery
bleeding.
Background: Diffuse microvascular bleeding is still a common problem after cardiac procedures. This study was
designed to evaluate the hemostatic effects of low-dose tranexamic acid in on-pump coronary artery bypass graft
surgery.
Methods: In this prospective randomized placebo-controlled study, 150 patients who were candidates for coronary
artery bypass were enrolled and randomly assigned to 1 of 2 groups (tranexamic acid or placebo). Total drainage volume
and the need for transfusion as well as surgical complications were recorded and compared in the 2 groups.
Results: There was significantly less mediastinal chest tube drainage up to 48 h in the tranexamic acid group
(432 210mL) compared to the placebo group (649 235mL, p¼ 0.006). In the placebo group, 43 (58%) patients
were given allogeneic blood during hospital stay compared to 22 (25%) in the tranexamic acid group (p< 0.001). No
significant difference in postoperative complications was seen.
Conclusion: The use of low-dose tranexamic acid can significantly reduce blood loss and need for transfusion, with no
increase in complications.
Keywords
Antifibrinolytic agents, blood transfusion, coronary artery bypass, postoperative hemorrhage, tranexamic acid
Introduction
Diﬀuse microvascular bleeding is still a common prob-
lem after cardiac procedures which account for more
than 700,000 surgeries per year.1 Of these, 50%–80%
were found to be of the medical rather than the surgical
kind.2 Fibrinolysis was shown to be responsible for
25%–45% of signiﬁcant post-bypass bleeding.3
Approximately 70% of these cases require antiﬁbrino-
lytic therapy.1 Systemic use of antiﬁbrinolytics reduces
postoperative blood loss. The 2 main classes of antiﬁ-
brinolytics used in coronary artery bypass grafting
(CABG) procedures are synthetic lysine analogues
such as epsilon-aminocaproic acid (EACA) and tranex-
amic acid (TA), and serine-protease inhibitors (apro-
tinin); both classes have been widely used for this
purpose and shown to decrease the incidence of
blood transfusions. However, consistent data or guide-
lines on the type of antiﬁbrinolytic drugs that should be
used and their appropriate dose and indications are still
unsatisfactory. Although antiﬁbrinolytics reduce
transfusion requirements, complication such as
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thromboembolism have been reported.4–6 Thus the
beneﬁt of antiﬁbrinolytic agents must be always mea-
sured in view of a possible increase in the risk of
thromboembolic complications that could result in
early graft closure. Moreover, these patients are at
increased risk of cerebral, pulmonary, mesenteric and
retinal artery, and venous thrombosis. Among antihe-
morrhagic drugs employed to prevent hemostatic
derangement in cardiac surgery performed with the
aid of cardiopulmonary bypass (CPB), "-aminocaproic
acid and TA, two synthetic low-cost antiﬁbrinolytic
drugs, have recently been investigated as alternatives
to the more expensive drug, aprotinin. Both "-amino-
caproic acid and TA act by forming a reversible com-
plex with plasminogen and plasmin through the lysine-
binding sites, thereby preventing interaction with the
speciﬁc lysine residues of ﬁbrin. TA is approximately
10-times more potent than "-aminocaproic acid.7
Decline in commercial approval for aprotinin forced
more clinicians to administer TA to patients at higher
risk of bleeding and adverse outcomes. Intravenously
administered TA (most commonly, 10mgkg1 fol-
lowed by infusion of 1mgkg1h1) brought about a
reduction of 29%–54% in postoperative blood loss
compared to placebo, in patients undergoing cardiac
surgery with CPB, with a signiﬁcant reduction in trans-
fusion requirement in some studies.5 Among some
retrospective analyses of observational data, the latest
suggest an increase in mortality, in contrast to the data
pertinent to the aprotinin era, among patients undergo-
ing surgery with opening of a cardiac chamber. In add-
ition, an increase in cerebral excitatory phenomena
(seizure activity) with TA has a known mechanism
and questions whether such patients should be treated
with this drug.8 This study aimed to examine potential
complications and the eﬀectiveness of systemic use of
low-dose TA to reduce blood loss after CABG.
Patients and methods
After obtaining institutional ethics committee
approval, all patients planned for primary isolated
elective CABG at Kashani Hospital, Shahrekord,
Iran, from March 2009 to November 2011, were scru-
tinized for this prospective randomized placebo-
controlled study. Patients who had emergency surgery,
rheumatic fever, bleeding diathesis (hemophilia or
platelet count <100 109L1), renal failure
(creatinine> 160mgdL1), known allergy or contra-
indication to TA (acquired visual defect, subarachnoid
hemorrhage, gall bladder disease, emboli, venous
thrombosis), recent (<7 days before surgery) intake of
Plavix or heparin, or streptokinase administration
within 48 h of operation, were excluded from
the study. There were 150 patients (60 men and
15 women) who satisﬁed the inclusion criteria. They
were informed about the use of TA during surgery
and its side eﬀects, and their informed consent was
obtained. The patients were randomly divided into 2
groups. The TA group included 75 patients who
received 10mgkg1 of TA added to the priming solu-
tion and a bolus dose of 1mgkg1 after weaning from
CPB and infusion of protamine sulphate. Retrograde
priming was not undertaken in all patients. The placebo
group included 75 patients who received 100mL of
normal saline per procedure, as described for the TA
group. Randomization was carried out by a staﬀ nurse
who prepared the 2 solutions in identical bottles and
delivered them to the operating room. Neither surgeon,
assistant, anesthetist, scrub nurse nor the perfusionist
knew the composition of the administered solutions.
Only one cardiac surgeon was responsible for the sur-
gical homeostasis.
The anesthetic management and CPB conduct were
standardized. All patients received heparin 300unitkg1
before CPB to achieve a target activated clotting
time5 480 s. During CPB, extra heparin was given
if necessary to maintain the target activated clotting
time. After weaning from CPB, heparin was reversed
using protamine sulphate in a dose of 1mg per 100
units of heparin, to achieve activated clotting time of
80–120 s in all patients. After transfer to the intensive
care unit, continuous low-grade suction (10–15 cm
H2O) and periodic milking of the drains were applied.
Hemoglobin level, hematocrit, platelet count, inter-
national normalized ratio, partial thromboplastin
time, and ﬁbrinogen level were measured prior to the
operation and on arrival in the intensive care unit. The
drainage of the chest tubes was measured hourly, and
they were removed when the total drainage was less
than 100mL over the previous 12 h and the secretions
were clear. All patients underwent a uniform transfu-
sion protocol. If hematocrit levels were <24% or the
hemoglobin levels4 8.0mg mgdL1 in the postopera-
tive period, a blood transfusion was carried out.
Postoperative complications including reoperation,
myocardial infarction (new Q wave >40ms duration
on an electrocardiogram obtained on the morning of
the 2nd postoperative day, increase in creatine kinase-
MB 5-times the upper limit of normal, and echo ﬁnd-
ings), pericardial eﬀusion, neurologic complications,
and renal injury were recorded. Surgical reexploration
was considered when coagulation variables were
normal and bleeding was greater than 500mL during
the ﬁrst 1 h, or >1000mL for 4 h consecutively.
Demographic data were analyzed using descriptive
tests and presented as mean standard deviation. Data
analysis of transfusion requirements and mediastinal
chest tube drainage (MCTD) was performed using
Fisher’s exact test, the chi-square test, and Student’s
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t test. To remove bias and time eﬀects, MCTD data
were analyzed using repeated measures analysis of vari-
ance. A p value less than 0.05 was considered statistic-
ally signiﬁcant.
Results
Mean age was 54.6 10.4 years in the placebo group
and 54.2 9.7 years in the TA group, and there was no
signiﬁcant diﬀerence in terms of age or sex based on the
t test (p¼ 0.94) and Fisher’s exact test (p¼ 0.94). The
48-h postoperative MCTD in the TA group was
432 210mL compared to 649 235mL in the placebo
group, with a signiﬁcant diﬀerence between groups
(p¼ 0.006; Figure 1). In the placebo group, 43 (58%)
patients were given allogeneic blood during hospital
stay compared to 22 (25%) in the TA group. In this
regard, there was a signiﬁcant diﬀerence between
groups (p< 0.001; Figure 2). There was no signiﬁcant
diﬀerence in morbidity or mortality between the 2
groups (Table 1).
Discussion
TA is used during cardiac surgery primarily to prevent
ﬁbrinolysis, but optimal doses, timing, and methods of
administration of TA are still debated. In our study, 75
patients received a placebo whereas the other 75
received 10mgkg1 of TA added to the priming solu-
tion and 1mgkg1 after weaning from CPB and injec-
tion of protamine sulphate, which is less than the dose
commonly used in cardiac surgery. We also discontin-
ued the treatment in the postoperative period.
Nevertheless, there was a signiﬁcant diﬀerence between
the 2 treatment groups with respect to MCTD up to
48 h and blood transfusions postoperatively. In some
studies with diﬀerent protocols, limited TA use during
surgical procedures has been proposed;9–12 while in
other studies originating from the report of Horrow
and colleagues,13 administration of TA infusion
during the ﬁrst hours of the postoperative period has
been supported.14–16 The plasma concentration
required to suppress ﬁbrinolysis in vitro is 10mgkg1,
and to suppress plasmin-induced platelet activation, it
is 16mgmL1.18–19 A study on the dose-response
Figure 1. Postoperative mediastinal chest tube drainage.
tran: tranexamic acid; plac: placebo.
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association showed a plateau eﬀect on drainage losses
with a total dose of 3 g of TA, while no eﬀect on trans-
fusions was seen.20 Intravenous TA in cardiac surgery
with CPB has been administered most commonly at
a dose of 10mgkg1 followed by infusion of
1mgkg1h1. TA at this dose caused reductions com-
pared to placebo of 29%–54% in postoperative blood
loss in patients undergoing cardiac surgery with CPB,
and signiﬁcant reductions in transfusion requirements
were obtained in some studies.5 In our study, TA treat-
ment during the surgical procedure caused a 33%
reduction in the need for allogeneic transfusions, com-
pared to placebo, which is similar to the ﬁndings when
TA was used at a higher dose.
According to our ﬁndings, consistent with the study
of Casati and colleagues,7 prolongation of treatment
with TA after cardiac surgery yields no advantage
over intraoperative administration alone in reducing
bleeding and the number of allogeneic transfusions.
A study by Pleym and colleagues21 showed that a
single dose of tranexamic acid before CPB signiﬁcantly
reduced postoperative bleeding in CABG patients trea-
ted with aspirin until the day before surgery. Lambert
and colleagues12 demonstrated the equivalence of the 3
doses of TA in primary cardiac surgical procedures.
Our study showed that the low dose (20mgkg1)
of TA resulted in comparable outcomes, without add-
itional complications. In a study by Armellin and col-
leagues22 in 250 patients planned for elective primary
coronary revascularization, one group received TA
30mgkg1 soon after the induction of anesthesia and
the same dose was added to the CPB prime solution,
Figure 2. Postoperative blood transfusion.
Table 1. Frequency of complications in 150 patients undergoing
coronary artery bypass.
Complication
Tranexamic
acid Placebo p value
Reoperation 1 1 0.752
Myocardial infarction 4 1 0.341
Pericardial effusion 5 3 0.359
Cerebrovascular accident 3 5 0.359
Acute tubular necrosis 2 1 0.5
Mortality 2 2 0.69
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whereas the other group received TA 15mgkg1 after
systemic heparinization followed by an infusion of
1mgkg1h1 until the end of the operation.
Transfusion of blood products, bleeding in the post-
operative period, and coagulation proﬁles were no dif-
ferent between the 2 groups. The study also
demonstrated that the diﬀerent start times of the ﬁrst
infusion and dosages of TA were equally eﬀective. It
appears to be safer, in theory, to administer TA when
patients are protected from thrombus formation by full
heparinization.
Because the TA half-life is approximately 80min,
approximately 30%, 45%, and 90% of the dose admin-
istered is recovered in urine after 1, 3, and 24 h, respect-
ively.23 Probably, the doses administered after weaning
from CPB are suﬃcient to last for the immediate post-
operative period without additional doses. The hetero-
geneity of the ﬁbrinolytic response to CPB was
described by Chandler and colleagues24 who also
demonstrated that ﬁbrinolysis is restricted in the post-
operative period by high levels of plasminogen activa-
tor inhibitor type 1, produced as part of the systemic
acute-phase response to surgical trauma. Although
MCTD is a variable routinely included in studies eval-
uating blood conservation measures, it is only a surro-
gate marker of allogeneic transfusions. In our study, in
the ﬁrst 24 h postoperatively when hematocrit is not a
suitable factor for deciding transfusion, MCTD was a
helpful. In our study, 1.33% of TA patients needed
reexploration for control of postoperative bleeding.
However, no signiﬁcant diﬀerence was observed
between the 2 groups. Reexploration for bleeding fol-
lowing cardiac surgery with CPB is reported to be 2%–
7%.25
Adverse eﬀects such as nausea and diarrhea were
uncommon in our patients, and TA was well tolerated,
similar to the report of Dunn and colleagues.5 Three
patients in the TA group and 5 in the placebo group
had a cerebrovascular accident. There was no signiﬁ-
cant diﬀerence in the frequency of cerebrovascular acci-
dent between the 2 groups. Also, we did not observe
seizure activity in our patients. Neurological outcomes
have long been a safety concern because administration
of TA has an association with clinically signiﬁcant cere-
bral vasospasm with acute cerebral hemorrhage.6
Several studies have independently detected increased
seizure activity.26,27 Based on our ﬁnding, the patients
in placebo group had surprisingly less postoperative
myocardial infarction compared to patients in TA
group, although this diﬀerence was not statistically sig-
niﬁcant. Future studies on the use of TA in cardiac
surgery should systematically record postoperative
myocardial ischemia and infarction. The possibility of
thromboembolic complications, in particular, graft
occlusion with myocardial ischemia and infarction
caused by TA, must be considered when giving this
drug to cardiac patients. Several publications have
highlighted this issue.28–31 There is no available evi-
dence that prophylactic use of TA causes graft occlu-
sion or other thromboembolic complications. However,
it should be born in mind that controlled clinical studies
are not suitable for detecting infrequent adverse drug
reactions.32 In our study, postoperative pericardial eﬀu-
sion and mortality showed no signiﬁcant diﬀerence
between the 2 groups.
Limitations of the study include the fact that the
number of the patients was relatively small. Larger
multicenter prospective controlled trials using a low
dose of TA are suggested to investigate its eﬀect in
procedures with a higher risk of bleeding, such as
repeat sternotomy, multiple valve, combined proced-
ures, or aortic arch operations. We concluded that
use of low-dose TA in primary isolated elective
CABG operations can signiﬁcantly reduce blood loss
and need for transfusion, without an increase in
complications.
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